Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
Hematology
How do you approach kit-mutated, core binding factor AML with an emphasis on prognosis, transplantation, targeted therapy.
Related Questions
Does treating CLL reduce the risk of non-melanoma skin cancers?
For patients with newly diagnosed AML who are induction chemotherapy eligible, do you dose reduce cytarabine for any mild elevation in AST/ALT?
In treatment naive patients with del 17p/TP53 negative CLL, will the recent interim analysis of fixed duration acalabrutinib plus venetoclax +/- obinutuzumab vs chemoimmunotherapy in the AMPLIFY trial (published in the NEJM) change your practice?
Do you add venetoclax +/- anti CD-20 mAb to a BTKi in patients with CLL who no longer wish to remain on a BTKi many months after starting the BTKi?
What would be an appropriate frontline AML regimen for transplant ineligible patients with chronic kidney disease (creatinine 2.5 or higher)?
What is your approach to treatment of relapsed, high-risk MDS with TP53 mutation in a patient that is not considered a transplant candidate?
How would you approach a young, fit patient with suspected CNS involvement with high circulating blasts?
how do you manage ocular hemorrhages while on acalabrutinib for CLL
How would you treat a patient with newly diagnosed low-risk acute promyelocytic leukemia who has a baseline wide QTc interval, such that arsenic trioxide cannot be used?
Is there therapeutic relevance for FLT3-ITD mutation in relapsed APML?
